The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
GTX Medical gains a new technology and loses a competitor
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Vindication is sweet for Seattle
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
A change of the guard for the world’s biggest cancer companies
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Alexion pays Achillion a $930m complement
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.